Aptamer Group PLC Block Listing Interim Review
February 25 2025 - 1:01AM
RNS Regulatory News
RNS Number : 2691Y
Aptamer Group PLC
25 February 2025
25
February 2025
Aptamer Group
plc
("Aptamer", the "Company" or the "Group")
Block Listing Interim
Review
Aptamer Group plc (AIM: APTA), the
developer of novel Optimer® binders to enable
innovation in the life sciences industry, makes the following
notification pursuant to AIM Rule 29 and Schedule 6 of the AIM
Rules for Companies regarding its existing block
admission:
|
Name of Company
|
Aptamer Group plc
|
|
Name of Scheme
|
The Aptamer Group EMI Share Option
Scheme
|
|
Period of Return
(from/to)
|
25 August 2024 to 24 February
2025
|
|
Number and class of securities not
issued at the start of the period under the scheme
|
1,666,477 Ordinary Shares
|
|
Number of securities issued under
the scheme during the period
|
0
|
|
Number of securities lapsed/waived
under the scheme during the period
|
1,090,424 Ordinary Shares
|
|
Balance under the scheme of
securities not yet issued at the end of the period
|
576,053 Ordinary Shares
|
|
Number and class of securities
originally admitted and the date of admission
|
2,063,200 Ordinary Shares on 25
February 2022
|
|
Name of contact and telephone
number
|
Andrew Rapson +44 (0) 1904 217
404
|
- Ends -
For
further information, please contact:
|
Aptamer Group plc
Arron Tolley, Chief Executive
Officer
|
+44 (0) 1904 217
404
|
|
SPARK Advisory Partners Limited - Nominated
Adviser
Andrew Emmott / Jade
Bayat
|
+44 (0) 20 3368
3550
|
|
Turner Pope Investments (TPI) Limited -
Broker
James Pope / Andrew
Thacker
|
+44 (0) 20 3657
0050
|
|
Northstar Communications Limited - Investor
Relations
Sarah Hollins
|
+44 (0) 113 730 3896
|
About Aptamer Group plc
Aptamer Group is a leading global
developer of aptamer-based ligands that help scientists remove the
limits to discovery and innovation. Leveraging several proprietary
discovery and development platform, Aptamer delivers custom
affinity ligands, supported with a complete suite of
characterisation and validatory assays that enhance the translation
of its binders and optimise scientific outcomes for
customers.
Aptamer's cutting-edge technology
spans healthcare, research, personal care, and industrial
processes, delivering new affinity solutions for novel targets,
advanced diagnostics, and precision therapies. By working with
industry leaders in pharmaceutical, biotechnology, personal health,
academic, and clinical research sectors, Aptamer is accelerating
science through the custom development of tools and
therapies.
To register for news alerts by email
go to https://aptamergroup.com/investors/investor-news-email-alerts/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
BLRDZLFLELLLBBV
Aptamer (LSE:APTA)
Historical Stock Chart
From Feb 2025 to Mar 2025
Aptamer (LSE:APTA)
Historical Stock Chart
From Mar 2024 to Mar 2025
